PBF (1760) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 寶齡富錦

PBF (1760) reported revenue of NT$156.2 million for Oct 2026, +16.7% year on year and +13.9% from the previous month. Revenue for Jan–Oct 2026 was NT$1.68 billion (+1.7% year on year).

In Oct 2026, it ranked No. 52 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$130.4 million24/10Nov 2024 NT$235.5 millionDec 2024 NT$156.6 millionJan 2025 NT$110.1 millionFeb 2025 NT$243.5 million25/02Mar 2025 NT$127.9 millionApr 2025 NT$135.2 millionMay 2025 NT$230.4 millionJun 2025 NT$138.2 million25/06Jul 2025 NT$144.9 millionAug 2025 NT$251.3 millionSep 2025 NT$135.8 millionOct 2025 NT$133.8 million25/10Nov 2025 NT$232.4 millionDec 2025 NT$180 millionJan 2026 NT$136.8 millionFeb 2026 NT$232.7 million26/02Mar 2026 NT$149.8 millionApr 2026 NT$144.6 millionMay 2026 NT$234.5 millionJun 2026 NT$132.7 million26/06Jul 2026 NT$173.2 millionAug 2026 NT$181.2 millionSep 2026 NT$137.2 millionOct 2026 NT$156.2 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$156.2 million+16.7%+13.9%
Sep 2026NT$137.2 million+1.1%-24.3%
Aug 2026NT$181.2 million-27.9%+4.6%
Jul 2026NT$173.2 million+19.6%+30.5%
Jun 2026NT$132.7 million-4.0%-43.4%
May 2026NT$234.5 million+1.8%+62.1%
Apr 2026NT$144.6 million+7.0%-3.5%
Mar 2026NT$149.8 million+17.1%-35.6%
Feb 2026NT$232.7 million-4.5%+70.1%
Jan 2026NT$136.8 million+24.3%-24.0%
Dec 2025NT$180 million+14.9%-22.6%
Nov 2025NT$232.4 million-1.3%+73.7%
Oct 2025NT$133.8 million+2.6%-1.4%
Sep 2025NT$135.8 million+3.7%-46.0%
Aug 2025NT$251.3 million+4.6%+73.5%
Jul 2025NT$144.9 million-4.8%+4.8%
Jun 2025NT$138.2 million+10.0%-40.0%
May 2025NT$230.4 million-1.6%+70.4%
Apr 2025NT$135.2 million+8.8%+5.7%
Mar 2025NT$127.9 million+4.7%-47.5%
Feb 2025NT$243.5 million+6.8%+121.2%
Jan 2025NT$110.1 million-26.2%-29.7%
Dec 2024NT$156.6 million+13.9%-33.5%
Nov 2024NT$235.5 million-5.8%+80.6%
Oct 2024NT$130.4 million-7.6%-0.4%

Jan–Oct 2026 cumulative: NT$1.68 billion (+1.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: PBF vs PEC / PBF vs Lotus Pharm / PBF vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16